Ophthotech: Investor Day (IVERIC bio) - Jan 2, 2016 - “FOVISTA® (1.5MG ANTI-PDGF) COMBINATION THERAPY MET THE PRE-SPECIFIED PRIMARY ENDPOINT”; “MEAN CHANGE IN VA (BASELINE TO WEEK 24)”; “Visual Outcome – Standard Baseline Variable”; “IMPROVED VISUAL OUTCOME, VISUAL LOSS/POOR VISUAL OUTCOME”
P2b data • Ophthalmology
|